Faron Pharmaceuticals doses first patient in BLAZE trial of bexmarilimab plus Opdivo
BMY•Faron Pharmaceuticals dosed the first patient in the Phase 1/2 BLAZE trial of bexmarilimab plus nivolumab in anti-PD-1-resistant solid tumors.
1. Trial begins
The investigator-initiated BLAZE trial is designed to generate safety and anti-tumor activity data in anti-PD-1-resistant non-small cell lung cancer and melanoma. Results have not been presented.
